Chipscreen Biosciences, Ltd.

This study tests a new combination of drugs (chiauranib, an immunotherapy, and two chemotherapies) as the first treatment for people with metastatic pancreatic cancer that has spread. About 558 adults aged 18-75 will take part. The goal is to see if the new combo works better tha…

This study looks at whether adding the drug Chiglitazar to standard SGLT-2 inhibitor therapy helps adults with type 2 diabetes achieve better blood sugar control. About 3,550 participants will be followed during their regular care to track changes in blood sugar, heart, kidney, a…

This early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a specific genetic deletion (MTAP). The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 186 adults who have run out of …

This study checks if a new pill that combines two diabetes drugs (Chiglitazar and Metformin) works the same as taking them separately. It involves 24 healthy adults who will take a single dose of each version under fed conditions. The goal is to measure how the drug moves through…

This study checks if a new tablet that combines two diabetes drugs (Chiglitazar and Metformin) is absorbed the same way as the standard separate tablets. It involves 64 healthy adults aged 18-45 who take a single dose of each version after a meal. The goal is to see if the new co…

This early-stage study tests a new combination pill for type 2 diabetes in 28 healthy Chinese adults. It has two parts: one checks how a high-fat meal changes drug levels in the blood, and the other looks at how the drug builds up with repeated doses. The goal is to gather safety…